Sofosvel Sofosbuvir Velpatasvir 400 MG

Sofosvel (Sofosbuvir+Velpatasvir) 400 MG

sofosbuvir-velpatasvir

Price: $120.00

Out of stock

Sofosbuvir-velpatasvir is a pangenotypic NS5A-NS5B inhibitor single-pill combination regimen that has potent activity against hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, and 6. It provides a much-needed option for patients with HCV genotype 3 infection, including those with compensated cirrhosis. Notably, an abbreviated duration of 8 weeks has not been studied with sofosbuvir-velpatasvir for any of the genotypes, except in conjunction with a third agent (voxilaprevir). Sofosbuvir-velpatasvir, like ledipasvir-sofosbuvir, may have have levels significantly reduced with acid-reducing agents, particularly proton-pump inhibitors.

whatsapp
Whatsapp +8801922101029
wechat
Wechat +8801922101029
Categories: , Tags: , ,

Description

Sofosvel(Sofosbuvir Velpatasvir) is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination of drug has approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel use without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).

Sofosvel indicate for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections

  • With or without cirrhosis or with compensated cirrhosis
  • With decompensated cirrhosis for use in combination with Ribavirin

Sofosbuvir+Velpatasvir is a direct-acting antiviral agent against the hepatitis C virus. It is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication.

It indicate for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.

Indications

Sofosbuvir and Velpatasvir combination is indicated for the prevention of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection-

  • Without cirrhosis or with compensated cirrhosis
  • With decompensated cirrhosis for use in combination with ribavirin

Therapeutic Class

Hepatic viral infections (Hepatitis C)

Pharmacology

It is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor.

Dosage & Administration

The recommended dosage is one tablet (400 mg of Sofosbuvir and 100 mg of Velpatasvir) taken orally once daily. Recommended treatment regimen:

  • Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A): one tablet once daily for 12 weeks
  • Patients with decompensated cirrhosis (Child-Pugh B or C): one tablet once daily and Ribavirin for 12 weeks. The recommended dosage of Ribavirin is based on bodyweight (1000 mg/day for patients < 75 kg and 1200 mg/day for ≥ 75 kg, in two divided dose/day)

Interaction

Drugs may decrease the concentrations of Sofosvel: Antacids, H2-receptor antagonists, Proton-pump inhibitors etc.

Coadministration is not recommended with: topotecan, Carbamazepine, Phenytoin, Phenobarbital, Oxcarbazepine, Rifabutin, Rifampin, Rifapentine, efavirenz, Tipranavir, Ritonavir, Hypericum perforatum.

Coadministration of Sofosbuvir and Velpatasvir combination, with Rosuvastatin, Atorvastatin may significantly increase the concentration of Rosuvastatin, Atorvastatin.

Contraindications

Sofosbuvir, Velpatasvir and Ribavirin combination regimen is contraindicated in patients for whom Ribavirin is contraindicated.

Side Effects

The most common side effects of drugs combination include headache and tiredness. Treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine use to treat certain heart problems).

Pregnancy & Lactation

No adequate human data are available to establish whether or not Capsule combination poses a risk to pregnancy outcomes. If Tablets combination administered with Ribavirin, the combination regimen contraindicate in pregnant women and in men whose female partner is pregnant or going to be pregnant in next six months.

Precautions & Warnings

Serious symptomatic bradycardia may occur in patients taking amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Co-administration of amiodarone with Sofosbuvir and Velpatasvir combination not to recommend. In patients without alternative viable treatment options, cardiac monitoring recommend.

Use in Special Populations

Renal impairment patient: No dosage recommendation give for patients with severe renal impairment (eGFR ≤30 mL/min/1.73 m2) or with ESRD, due to higher exposures of the predominant sofosbuvir metabolite.

Visit our another product here:

No images in this gallery yet!